OUR TEAM

Brett Sandercock
Non Executive Chairman (B,Econ, C.A. (Aust))

Brett Sandercock was appointed chief financial officer of Resmed Limited (NYSE: RMD, ASX: RMD) in January 2006. Previously, he served as ResMed's vice president of Treasury and Finance from November 2004 until December 2005, and group accountant and controller from 1998 to 2004.

Before joining ResMed, Mr Sandercock was manager of Financial Accounting and Group Reporting at Norton Abrasives, a division of Saint-Gobain, a French multinational corporation, from 1996 to 1998. He also held finance and accounting roles from 1994 to 1996 at Health Care of Australia, a large private hospital operator. From 1989 to 1994, he worked at Pricewaterhouse Coopers in Sydney, specializing in audits of clients across distribution and manufacturing, financial services, technology, and other industries.

Mr Sandercock holds a bachelor's in economics from Macquarie University in Sydney, and is a Chartered Accountant.


Professor Teoh Swee Hin
Non Executive Director (B Eng (1st Hons), PhD Materials Engineering (Singapore))

Prof Teoh Swee Hin, is the President's Chair, School of Chemical and Biomedical Engineering (SCBE). He holds a joint appointment with the Lee Kong Chian School of Medicine (LKC Med) at Nanyang Technological University. His contribution is in the development and clinical translation of 3D bioresorbable scaffolds. Majoring in Materials Engineering (B. Eng -1st Class Hon and PhD, Monash University), his research journey focused at translating the materials research to biomedical benefits. He is a Fellow of the Academy of Engineers Singapore and Chief Engineer at Skin Research Institute of Singapore. His research focused on the study of mechanisms that promote cells proliferation and differentiation as a result of mechno induction through load bearing scaffolds for tissue regeneration and remodelling.

BProf Teoh's pioneering work on 3D printed scaffold led to him receiving the prestigious "Golden Innovation Award" at the Far East Economic Review, and the Institute of Engineers "Prestigious Engineering Achievement Award" in 2004. His group was ranked 1st in bone tissue engineering scaffolds in World Web of Science 2010. He was honoured with the Special Award for "Scientific Life-Time Achievement in Bone Tissue Engineering" at Bone-Tec 2015, Stuttgart. As a part of SG50 celebrations, he was featured as one of Singapore's profiled scientists in the book titled "Singapore's Scientific Pioneers".

Professor Teoh is presently the Chairman, Singapore Academy, Asia Regulatory Professional Association (ARPA). He sits in as board of editors Tissue Engineering, Journal of Tissue Engineering and Regenerative Medicine, Journal of Mechanical Behaviour of Biomedical Materials, Journal of Oral & Maxillofacial Research and Proceedings of the Institution of Mechanical Engineers Part H: Journal of Engineering in Medicine.


Stuart Carmichael
Non-Executive Director (B.Com, C.A (Aust))

Mr Carmichael is a Chartered Accountant with over 20 years of experience in the provision of corporate advisory services both within Australia and internationally. Mr Carmichael is a partner and director of Ventnor Capital Pty Ltd and Ventnor Securities Pty Ltd which specialises in the provision of corporate and financial advice to small cap ASX listed companies including capital raisings, initial public offerings, corporate restructures and mergers and acquisitions.

Mr Carmichael completed a Bachelor of Commerce at the University of Western Australia and is qualified with Institute of Chartered Accountants of Australia and New Zealand.

Mr Carmichael also acts as Non-Executive Chairman of Schrole Ltd (ASX:SCL), Non-Executive Chairman of Serpentine Technologies Ltd (ASX:S3R), Non-Executive Director of De.mem Limited (ASX:DEM) and Non-Executive Director of ClearVue Technologies Limited (ASX:CPV).


Geoff Pocock
Executive Director (BSc (1 Hons), B. LLB (Aust))

Mr Geoff Pocock has significant experience as a corporate advisor and strategy consultant advising companies on commercialisation and IP management, business development, mergers and acquisitions strategy and raising equity capital from private and public equity markets.

Mr Pocock is currently the principal of Polaris Consulting (WA) Pty Ltd, and was formerly the Managing Director of Hazer Group Ltd (ASX: HZR), an ASX-listed cleantech chemical engineering company, commercialising a novel low cost and low emission graphite and hydrogen production process initially developed by the University of Western Australia.

Mr Pocock has a Bachelor of Science with first class honours and a Bachelor of Law from the University of Western Australia, and has completed a Postgraduate Diploma in Applied Finance and Investment from the Securities Institute of Australia. Mr Pocock previously spent several years as a research scientist in the biopharmaceutical industry in Australia and the United Kingdom.

Mr Pocock acts as Non-Executive Director of Emvision Medical Devices Limited (ASX:EM1).


Goh Khoon Seng
Chief Executive Officer (M.Eng (Mech) (Singapore))

Mr Goh's 30-year career spans both start-ups and global multinational corporations, with responsibilities in research & development, manufacturing, regional sales and marketing, and country management. Prior to joining Osteopore Mr Goh spent over 20 years with Medtronic plc (Medtronic plc is the world's largest medical device company) and Edwards Lifesciences Asia in various senior management roles.

Mr Goh has been a Director of Osteopore Pte Ltd, since 2015 and has been involved in all aspects of the Company.

Mr Goh holds a Masters in Engineering (National University of Singapore) and post graduate diploma with Chartered Institute of Marketing (UK).


Lim Jing
Chief Technology Officer (Ph.D. (Singapore))

Dr. Lim holds a PhD from Nanyang Technological University, Singapore. Prior to joining Osteopore, Dr. Lim conducted research on biomaterials for tissue engineering and regenerative medicine, and developed material fabrication platforms. Dr. Lim published 14 articles in internationally peer-reviewed journals in that time. Dr. Lim joined Osteopore in December 2014, and has led Osteopore to important regulatory and quality milestones. In addition, Dr. Lim led the expansion of product and therapy portfolio, and contributed to the improvement in manufacturing efficiency.